Longevity Breaks the Tables
馃憡馃徑 Hoolie 馃憡馃徑@hoolie
+0.9%
since Oct 12
The idea
I believe GLP-1s, peptides and longevity protocols will cut death rates faster than insurers' mortality tables assume, and that insurers will only update those tables gradually, leaving a pricing gap. To capture it, the portfolio leans into protection-focused life insurers and reinsurers who benefit most directly from fewer claims, with smaller stakes in the drugmakers driving the shift, next-wave obesity treatments, and the telehealth platforms distributing them. It deliberately skips annuity-heavy insurers, who lose when people live longer, and keeps a small cash buffer.
What it owns
- These companies mostly pay out when policyholders die, so fewer and later deaths than priced into their tables means more profit. 路 Globe Life Inc.It sells life insurance mainly to working-age, middle-income families, so fewer deaths than priced flow almost straight to profit., Primerica, Inc.It sells term life policies to families in the ages where GLP-1s are expected to drive the biggest drop in mortality., MetLife, Inc.It insures millions of workers through employer group life plans, a large working-age pool whose death rates could fall, while group life remains a significant earnings component., Manulife Financial CorporationIt carries a large life insurance book across North America and Asia, so it gains if longer lives show up in more countries than the US alone.33%
- These companies hold mortality risk for other insurers and pay fewer claims when working-age people get healthier, so death rates falling below historical tables flows directly to profit. 路 Reinsurance Group of America, IncorporatedIt takes on mortality risk from other life insurers, so it directly owns fewer deaths than actuarial tables assume, and its research projects GLP-1s will cut US mortality., Aflac IncorporatedIt sells supplemental health and life coverage to customers whose claim rates may trend lower, with Japan operations large enough to anchor results., Unum GroupIt writes group life and disability coverage for working-age people, whose claims from obesity-linked conditions like heart disease and diabetes may decline.26%
- These companies make the drugs driving the drop in death rates, so wider use spreads the effect that improves outcomes for mortality-sensitive businesses. 路 Eli Lilly and CompanyIt makes tirzepatide, one of the main drugs actually causing the drop in death rates, and has next-generation candidates in development., Novo Nordisk A/SIt makes semaglutide, the other drug driving how many people are on GLP-1s, and that reach is what pushes death rates down.17%
- Newer pills and longer-acting shots in development could widen the population that can take these drugs and stay on them consistently. 路 Amgen Inc.It is developing a once-a-month obesity shot, which could make it easier for more people to stay on treatment for years., Pfizer Inc.Its obesity pipeline represents a bet that more companies selling these drugs means lower prices and wider use across populations., Viking Therapeutics, Inc.It is developing obesity drugs in shot and pill form, a bet that the next wave of treatments will widen who gets access to these drugs., Structure Therapeutics Inc.It is building a daily GLP-1 pill, which could reach people who won't take a weekly shot and expand the total population on treatment.10%
- Telehealth platforms are how many people actually access GLP-1s and longevity-focused care outside traditional doctor's offices. 路 Hims & Hers Health, Inc.It sells weight loss drugs and longevity-focused care straight to consumers online, which is part of how these treatments spread past traditional doctor's offices., LifeMD, Inc.It runs telehealth weight management programs that prescribe GLP-1s, another route for getting these drugs to more people at scale.6%
- Cash8%